A Phase 1b Multi-Center, Randomized, Double-Blind, Multi−Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Plasma Exposure of TD−1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis

Trial Profile

A Phase 1b Multi-Center, Randomized, Double-Blind, Multi−Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Plasma Exposure of TD−1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs TD 1473 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Theravance Biopharma
  • Most Recent Events

    • 08 Aug 2017 Data (n=10) from first cohort of this trial published in a Theravance BiopharmaMedia Release.
    • 08 Aug 2017 According to a Theravance Biopharma media release, data from the remaining cohorts of this trial are expected in 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top